The Efficacy of Immunotherapy and Chemoimmunotherapy in STK11, KEAP1 & KRAS Gene Mutations in Advanced Non-small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Cheung, T. W. [1 ]
Morales, J. [1 ]
Sacks, H. [2 ]
Rolfo, C. [2 ]
机构：
[1] Northshore Univ Hosp, Manhasset, NY USA
[2] Mt Sinai Med Ctr, New York, NY 10029 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
PDL1; immunotherapy; meta-analysis;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP11.03-24
引用
收藏
页码：S630 / S630
页数：1
相关论文
共 50 条
  • [1] Probing Mutant KRAS, STK11, KEAP1 in NSCLC
    Poh, Alissa
    [J]. CANCER DISCOVERY, 2022, 12 (10) : 2226 - 2226
  • [2] STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?
    Di Federico, Alessandro
    De Giglio, Andrea
    Parisi, Claudia
    Gelsomino, Francesco
    [J]. EUROPEAN JOURNAL OF CANCER, 2021, 157 : 108 - 113
  • [3] Efficacy of chemoimmunotherapy in a lung adenocarcinoma patient with mutations in the KRAS and STK11
    Krzyzanowska, Natalia
    Krawczyk, Pawel
    Chmielewska, Izabela
    Jankowski, Tomasz
    Wojas-Krawczyk, Kamila
    Milanowski, Janusz
    [J]. ONCOLOGY IN CLINICAL PRACTICE, 2023, 19 (03): : 197 - 202
  • [4] Prevalence of STK11, KEAP1, and KRAS mutations/co-mutations and associated clinical outcomes for patients newly diagnosed with metastatic non-small cell lung cancer
    Dabbous, Firas
    Wang, Ching-Yu
    Simmons, Daniel
    Huse, Samuel
    Jassim, Rami
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Impact of STK11 and KRAS co-mutations on outcomes with immunotherapy in non-small cell lung cancer.
    Basher, Fahmin
    Saravia, Diana
    Fanfan, Dino
    Cotta, Jared Addison
    Lopes, Gilberto
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Concurrent Mutations in STK11 and KEAP1 Cause Treatment Resistance in KRAS Wild-type Non-small-cell Lung Cancer
    Sumii, Masahiko
    Namba, Masashi
    Tokumo, Kentaro
    Yamauchi, Masami
    Okamoto, Wataru
    Hattori, Noboru
    Sugiyama, Kazuhiko
    [J]. INTERNAL MEDICINE, 2023, 62 (20) : 3001 - 3004
  • [7] Comparative bioinformatic analysis of KRAS, STK11 and KEAP1 (co-) mutations in non-small cell lung cancer with a special focus on KRAS G12C
    Boeschen, Myriam
    Kuhn, Christina Katharina
    Wirtz, Hubert
    Seyfarth, Hans-Jurgen
    Frille, Armin
    Lordick, Florian
    Hacker, Ulrich T.
    Obeck, Ulrike
    Stiller, Mathias
    Blaker, Hendrik
    von Laffert, Maximilian
    [J]. LUNG CANCER, 2023, 184
  • [8] Effect of STK11 mutations on efficacy of PD-1 inhibition in non-small cell lung cancer (NSCLC) and dependence on KRAS mutation status.
    Ricciuti, Biagio
    Arbour, Kathryn Cecilia
    Lin, Jessica Jiyeong
    Vokes, Natalie
    Hoojghan, Amir Vajdi
    Li, Yvonne Y.
    Cherniack, Andrew D.
    Recondo, Gonzalo
    Lamberti, Giuseppe
    Venkatraman, Deepti
    Rizvi, Hira
    Egger, Jacklynn, V
    Plodkowski, Andrew J.
    Khosrowjerdi, Sara
    Digumarthy, Subba R.
    Nishino, Mizuki
    Sholl, Lynette M.
    Gainor, Justin F.
    Hellmann, Matthew David
    Awad, Mark M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] STK11 mutations in non-small cell lung cancer (NSCLC): descriptive analysis and prognostic significance
    Facchinetti, Francesco
    Bluthgen, Maria Virginia
    Clain, Gabrielle Tergemina
    Faivre, Laura
    Pignon, Jean-Pierre
    Planchard, David
    Soria, Jean-Charles
    Besse, Benjamin
    Lacroix, Ludovic
    [J]. CANCER RESEARCH, 2016, 76
  • [10] Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting
    Julian, Cristina
    Pal, Navdeep
    Gershon, Anda
    Evangelista, Marie
    Purkey, Hans
    Lambert, Peter
    Shi, Zhen
    Zhang, Qing
    [J]. BMC CANCER, 2023, 23 (01)
12345